{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luo F"],"funding":["Fundamental Research Funds for the Central Universities, Sun Yat-sen University","Natural Science Foundation of Guangdong Province","China Postdoctoral Science Foundation","National Natural Science Foundation of China","Fostering Program for NSFC Young Applicants (Tulip Talent Training Program) of Sun Yat-sen University Cancer Center","Young Talents Program of Sun Yat-sen University Cancer Center"],"pagination":["e14486"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12948199"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(12)"],"pubmed_abstract":["The ubiquitin-editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20-mediated IKK-β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin-NACRT) or capecitabine-only neoadjuvant chemoradiotherapy (non-oxaliplatin-NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin-NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 e"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β."],"pmcid":["PMC12948199"],"funding_grant_id":["YTP-SYSUCC-0104","2024M753753","82 303 807","24qnpy283","2024A1515013011","82 203 649","2025yfd18","82 473 398"],"pubmed_authors":["Chen Q","Xia Z","Cao J","Lu Z","Luo F","Li P","Lu F","Zhang R","Ma W","Yang Y","Lin C","Luo M","Yang T"],"additional_accession":[]},"is_claimable":false,"name":"A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK-β.","description":"The ubiquitin-editing enzyme A20 is essential for maintaining inflammatory homeostasis, yet its role in chemoresistance remains unclear. To investigate how A20 regulates oxaliplatin resistance in colorectal cancer (CRC), with a focus on A20-mediated IKK-β monoubiquitylation at K163. A prospective, randomized Phase III study is conducted in patients with locally advanced CRC who received either oxaliplatin+capecitabine neoadjuvant chemoradiotherapy (oxaliplatin-NACRT) or capecitabine-only neoadjuvant chemoradiotherapy (non-oxaliplatin-NACRT). Preoperative biopsy and matched surgical specimens are evaluated by immunohistochemistry to determine A20's association with oxaliplatin response. In oxaliplatin-NACRT group, patients achieving pathological complete response (pCR) displayed lower A20 e","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T22:20:31.506Z","creation":"2026-07-11T03:12:11.776Z"},"accession":"S-EPMC12948199","cross_references":{"pubmed":["41405367"],"doi":["10.1002/advs.202514486"]}}